Soligenix (NASDAQ:SNGX) Issues Earnings Results

Soligenix (NASDAQ:SNGX) released its quarterly earnings results on Friday. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, beating the consensus estimate of ($0.10) by $0.05, Zacks reports.

Soligenix Stock Up 0.5%

Shares of Soligenix stock traded up $0.00 during trading on Friday, hitting $0.34. 115,354 shares of the stock traded hands, compared to its average volume of 2,349,440. The stock has a market cap of $4.97 million, a price-to-earnings ratio of -0.34 and a beta of 2.04. The firm’s fifty day moving average is $0.36 and its 200-day moving average is $0.67. Soligenix has a 52 week low of $0.28 and a 52 week high of $1.70.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Soligenix in a research report on Thursday, October 15th. One equities research analyst has rated the stock with a Sell rating. According to MarketBeat, the company has an average rating of “Sell”.

About Soligenix

Soligenix, Inc is a U.S.-based biopharmaceutical company focused on developing treatments for rare diseases and serious medical conditions with limited therapeutic options. The company’s programs are primarily aimed at immunology, inflammation, infectious diseases and oncology, with an emphasis on advancing candidates through clinical development and regulatory approval.

Soligenix’s pipeline has included SGX301, a synthetic hypericin-based photodynamic therapy being developed for cutaneous T-cell lymphoma; SGX942, an innate defense regulator investigated for inflammatory conditions such as oral mucositis; and SGX945, a related candidate studied for Behçet’s disease.